United States Drug Patent RE44733: Scope, Claims, Expiration, and Sugammadex Patent Landscape
U.S. Patent RE44,733 covers substituted 6-mercapto-cyclodextrins, pharmaceutical compositions, neuromuscular-blockade reversal kits, and methods of reversing drug-induced neuromuscular block. Its commercially important subject matter is sugammadex, identified in the claims as 6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin and its sodium salt. The patent is a reissue of U.S. Patent No. 6,670,340 and expired in November 2020 based on the underlying patent term. It therefore presents no current U.S. blocking patent right, although its claim structure remains important for historical validity, freedom-to-operate, and patent-family analysis.
What does U.S. Patent RE44733 cover?
RE44,733 covers a genus of chemically modified cyclodextrins in which sulfur substituents are attached at the 6-position of the cyclodextrin glucose units. The claims extend across:
- Beta-cyclodextrin and gamma-cyclodextrin ring systems.
- Partially substituted and fully substituted derivatives.
- Carboxylic acid, sulfonic acid, phosphonic acid, hydroxyl, polyether, amide, and tetrazole terminal groups.
- Free acids and pharmaceutically acceptable salts.
- Pharmaceutical compositions.
- Kits combining a neuromuscular blocking agent with the cyclodextrin derivative.
- Parenteral methods for reversing neuromuscular block.
The claim set is directed principally to supramolecular encapsulation of steroidal neuromuscular blocking agents. The cyclodextrin derivative binds the neuromuscular blocker and reduces its free concentration at the neuromuscular junction.
What is the central chemical structure?
The core structure is a 6-mercapto-cyclodextrin derivative represented by the patent’s general Formula I:
- m is 0-7.
- n is 1-8.
- m+n equals 7 or 8.
- R is a C1-6 alkylene group, optionally containing one to three hydroxyl groups, or a substituted phenylene-containing linker.
- X is a terminal acidic or polar group, including COOH, SO2OH, PO(OH)2, hydroxyl, polyether, amide, or tetrazolyl.
- The compounds may exist as pharmaceutically acceptable salts.
The requirement that m+n equal 7 or 8 ties the genus to beta-cyclodextrin and gamma-cyclodextrin frameworks. Gamma-cyclodextrin has eight glucose units and is the relevant scaffold for sugammadex.
How broad is claim 1 of RE44733?
Claim 1 is a broad chemical genus claim. It does not require a particular neuromuscular blocking agent, medical indication, dosage, administration route, or formulation. A compound can fall within claim 1 if it satisfies the structural limitations and does not fall within one of the express exclusions.
The principal scope elements are:
| Limitation |
Claim effect |
| 6-Mercapto-cyclodextrin |
Requires sulfur-based substitution at the cyclodextrin 6-position |
| m+n = 7 or 8 |
Limits the cyclodextrin framework to beta or gamma systems |
| n = 1-8 |
Covers mono- through fully substituted derivatives |
| R linker |
Covers alkylene, hydroxylated alkylene, and phenylene-containing linkers |
| X terminal group |
Covers multiple acidic, polar, and ionizable functionalities |
| Pharmaceutically acceptable salt |
Covers sodium and other acceptable salt forms |
| Express exclusions |
Removes seven specifically identified prior compounds |
The claim does not require that every available 6-position be substituted. It covers compounds with one through eight sulfur-containing substituents, subject to the m+n condition. Claim construction would therefore turn on the relationship between m, n, the cyclodextrin ring size, and the structural meaning assigned to the phrase “6-mercapto-cyclodextrin derivative.”
What compounds are excluded from claim 1?
Claim 1 expressly excludes seven compounds or compound classes, including:
- Fully substituted and mono-substituted 2-hydroxyethylthio-β-cyclodextrins.
- Fully substituted 2-hydroxyethylthio-γ-cyclodextrin.
- Fully substituted and mono-substituted carboxymethylthio-β-cyclodextrins.
- A dideoxy bis(o-carboxyphenylthio)-β-cyclodextrin.
- A dideoxy bis(carboxymethylthiol)-β-cyclodextrin.
- Fully substituted 2,3-dihydroxypropylthio-β-cyclodextrin.
These exclusions narrow the broad genus to distinguish the claimed subject matter from known or cited compounds. They also create potential prosecution-history and written-description issues if an accused compound is structurally close to an excluded species.
Which claims specifically cover sugammadex?
Claims 11-21 expressly target 6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin, the active cyclodextrin component of sugammadex.
| Claim |
Subject matter |
| 11 |
The 2-carboxyethylthio fully substituted gamma-cyclodextrin |
| 12 |
The sodium salt |
| 13 |
Pharmaceutical composition containing the compound |
| 14 |
Pharmaceutical composition containing the sodium salt |
| 15 |
Neuromuscular-block reversal kit containing the compound |
| 16 |
Kit containing the sodium salt |
| 17 |
Kit with specified neuromuscular blockers |
| 18 |
Kit with rocuronium |
| 19 |
Kit with vecuronium |
| 20 |
Method of reversing neuromuscular block |
| 21 |
Method using the sodium salt |
Claims 11 and 12 are composition-of-matter claims. They are narrower than claim 1 but materially stronger against a competing product containing the specifically claimed active ingredient. Claims 13-19 add pharmaceutical, kit, and combination limitations. Claims 20 and 21 are method-of-treatment claims requiring parenteral administration for reversal of drug-induced neuromuscular block.
What are the most commercially important claims?
Claims 11, 12, 20, and 21 are the commercially important claims.
Claims 11 and 12 protect the active compound and its sodium salt. A product containing the claimed cyclodextrin as its active ingredient would have been exposed to direct composition-of-matter infringement.
Claims 20 and 21 cover administration of the compound to reverse a drug-induced neuromuscular block. They are relevant to clinical use of sugammadex, particularly where the treatment is used after rocuronium or vecuronium administration.
Claims 15-19 cover kits and combinations. A commercial package containing sugammadex and a neuromuscular blocking agent could implicate these claims, although infringement analysis would depend on product configuration, labeling, ownership or control of kit components, and the specific claim construction.
How does the patent cover rocuronium reversal?
Claims 6-8 and 15-19 expressly identify rocuronium. The claims are not limited to rocuronium, however. Claim 7 lists rocuronium, vecuronium, pancuronium, rapacuronium, mivacurium, cisatracurium, atracurium, tubocurarine, and suxamethonium. Claim 8 narrows the kit to rocuronium. Claims 18 and 19 separately narrow the compound-specific kits to rocuronium and vecuronium.
The patent therefore establishes two related protection layers:
- A broad compound layer covering the modified cyclodextrin.
- A clinical-use and combination layer covering reversal of neuromuscular block, particularly rocuronium-induced block.
The compound claims do not require rocuronium. A product could infringe the composition claims regardless of which neuromuscular blocker it reverses.
What is the patent expiration date of RE44733?
RE44,733 derives from U.S. Patent No. 6,670,340. The underlying patent was filed in November 2000 and issued on December 30, 2003. Its standard 20-year term expired in November 2020, subject to the applicable patent-term adjustment and any terminal-disclaimer treatment reflected in the official patent record.[1]
The reissue did not create a new patent term. A reissue patent generally carries the unexpired portion of the original patent term rather than restarting the patent term. RE44,733 therefore has no enforceable U.S. patent term in 2026.
Was there FDA regulatory exclusivity separate from the patent?
Yes. Sugammadex, marketed as Bridion, received FDA approval on December 15, 2015. The product received new chemical entity exclusivity, which ordinarily provided five years of regulatory exclusivity, subject to the timing of abbreviated application submissions and any applicable pediatric extension.[2]
FDA regulatory exclusivity and patent exclusivity are separate rights. The expiration of RE44,733 did not itself determine the end of FDA exclusivity, and the end of FDA exclusivity did not revive the patent.
What was the Orange Book status of RE44733?
The Orange Book historically identified patent protection for Bridion and its active ingredient, sugammadex sodium. The relevant patent family included U.S. Patent No. 6,670,340, of which RE44,733 is the reissue. Orange Book listings are product-specific and can include composition, method-of-use, formulation, or other patent information supplied by the NDA holder.[3]
Because RE44,733 is expired, it does not currently create a live Orange Book barrier to an ANDA applicant. Historical Orange Book listings remain relevant to:
- The timing of generic development.
- Paragraph IV certifications.
- ANDA litigation history.
- Settlement and launch timing.
- Assessment of whether a generic applicant challenged the original patent or a later patent family.
Were there Paragraph IV challenges to sugammadex patents?
Generic applicants seeking approval for sugammadex could use a Paragraph IV certification against listed patents that remained in force. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.
The principal historical target would have been the original sugammadex composition-of-matter patent family, including U.S. Patent No. 6,670,340 and the RE44,733 reissue. Later patents, if listed for Bridion, could have addressed formulation, dosing, manufacturing, or additional methods of use.
The four-year stay under the Hatch-Waxman Act would have been relevant only if the NDA holder or patent owner filed a timely infringement action after receiving the Paragraph IV notice. Once the principal composition patent expired, a Paragraph IV challenge to that patent no longer presented a long-term launch barrier, although litigation could still have affected the timing of approval or launch.
What patents protect sugammadex beyond RE44733?
The broader sugammadex estate historically included several categories of patents:
Composition-of-matter patents
These cover modified gamma-cyclodextrins with anionic side chains, including the carboxyethylthio structure used in sugammadex. RE44,733 is the principal patent identified by the supplied claims.
Method-of-use patents
These cover reversal of neuromuscular block, including reversal after administration of rocuronium or vecuronium. Claims 6-10 and 15-21 of RE44,733 contain this type of protection.
Formulation patents
Later patents may address injectable formulations, concentration, pH, stability, impurities, or excipient systems. Such patents can remain relevant after expiration of a composition patent if they claim a non-obvious formulation that a generic product practices.
Manufacturing patents
Process patents may cover the preparation of fully substituted cyclodextrin derivatives, control of substitution level, purification, crystallization, salt formation, or removal of residual starting materials and intermediates. These patents can create manufacturing barriers even when the active compound itself is off-patent.
Regulatory and labeling patents
Method-of-use patents can affect labeling strategy. A generic applicant may seek a full label, a skinny label, or approval limited to unpatented uses, depending on the scope and enforceability of listed method claims.
RE44,733 itself is not a manufacturing patent. Its claims focus on the compound, pharmaceutical compositions, kits, and reversal methods.
How strong was the patent estate?
Historically, the estate was strong because it combined a broad genus claim with narrow compound claims directed to the commercial active ingredient.
| Protection layer |
Historical strength |
Current status |
| Broad modified cyclodextrin genus |
High, subject to exclusions and validity limits |
Expired |
| Sugammadex compound claim |
Very high |
Expired |
| Sodium salt claim |
High |
Expired |
| Pharmaceutical composition claims |
Moderate to high |
Expired |
| Kit claims |
Moderate |
Expired |
| Rocuronium and vecuronium use claims |
Moderate |
Expired |
| Formulation or manufacturing patents |
Depends on later family |
Must be assessed separately |
The strongest historical claim was the specific composition claim for 6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin. A challenger could attack the genus through written description, enablement, anticipation, obviousness, or indefiniteness. Those arguments would have had less practical value against the specific sugammadex claims unless prior art disclosed the exact structure or an obvious route to it.
What generic launch risks exist for sugammadex?
The original RE44,733 risk has ended because the patent term expired. Current generic launch analysis must focus on later patents and regulatory barriers rather than RE44,733.
Key issues include:
- Whether later Orange Book-listed patents remain unexpired.
- Whether the proposed generic uses the same sodium salt and formulation.
- Whether the generic label includes patented reversal indications.
- Whether manufacturing steps practice later process claims.
- Whether injectable formulation parameters fall within later formulation claims.
- Whether a product is approved through an ANDA or another FDA pathway.
- Whether exclusivity, pediatric extensions, or regulatory stays remain relevant.
A generic manufacturer that makes and sells the same sugammadex sodium active ingredient after expiration of RE44,733 does not face infringement liability under the expired patent. Liability could still arise under a different unexpired patent.
Which companies compete in the sugammadex market?
Merck is the originator and commercial sponsor associated with Bridion. The patent estate was developed through the Organon/Merck group, with Merck becoming the principal commercial rights holder after its acquisition of Schering-Plough and related Organon assets.
Competition has expanded through generic manufacturers and suppliers pursuing abbreviated approval or equivalent injectable products. The principal competitive variables are:
- FDA approval timing.
- Product quality and impurity control.
- Manufacturing cost.
- Hospital formulary access.
- Supply reliability.
- Pricing relative to Bridion.
- Residual patent and litigation exposure.
Sugammadex competes clinically with older reversal approaches based on neostigmine and anticholinergic coadministration, although those products are pharmacologically and commercially distinct from sugammadex.
What is the revenue exposure associated with RE44733?
RE44,733 was economically important because it protected the active ingredient used in Bridion, a hospital-administered product used to reverse rocuronium- and vecuronium-induced neuromuscular block. The patent supported branded pricing during the protected period.
After patent expiration, revenue exposure shifted from composition-of-matter erosion to:
- Generic price competition.
- Hospital contracting.
- Formulation differentiation.
- Manufacturing scale.
- Brand loyalty and clinical adoption.
- Additional patent protection for later formulations or processes.
Exact product revenue cannot be attributed solely to RE44,733 because exclusivity depended on the combined effect of patents, FDA regulatory exclusivity, manufacturing capability, and market adoption.
Key Takeaways
- RE44,733 is a reissue of U.S. Patent No. 6,670,340.
- It covers 6-mercapto-cyclodextrin derivatives, pharmaceutical compositions, reversal kits, and neuromuscular-blockade reversal methods.
- Claims 11-21 specifically cover sugammadex and sugammadex sodium.
- Claims 8, 18, and 19 expressly address rocuronium and vecuronium kits.
- The patent’s broadest commercial value came from its composition-of-matter protection.
- The patent term expired in November 2020.
- RE44,733 does not present a current U.S. blocking patent risk.
- Current sugammadex diligence must examine later formulation, manufacturing, method-of-use, and Orange Book-listed patents.
- A Paragraph IV strategy would now target any later unexpired listed patents rather than the expired RE44,733 rights.
FAQs
Is RE44733 still enforceable against a sugammadex generic?
No. The patent term derived from U.S. Patent No. 6,670,340 expired in November 2020. Later patents must be analyzed separately.
Does RE44733 cover sugammadex sodium?
Yes. Claims 12, 14, 16, and 21 expressly recite the sodium salt of 6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin.
Does RE44733 cover reversal of rocuronium block?
Yes. Claims 8 and 18 specifically identify rocuronium, while broader claims cover reversal of drug-induced neuromuscular block without limiting the blocking agent to rocuronium.
Can a generic omit rocuronium from its label to avoid RE44733?
That issue was historically relevant to method-of-use claims, but it does not create a current barrier under the expired patent. A label strategy may still matter for later unexpired method patents.
Is sugammadex protected by biosimilar law?
No. Sugammadex is a small-molecule drug, not a biologic. Generic products are generally reviewed under the ANDA pathway rather than the biosimilar pathway under the Public Health Service Act.
References
- U.S. Patent and Trademark Office. (2014). 6-Mercapto-cyclodextrin derivatives and methods of use thereof (U.S. Patent No. RE44,733 E).
- U.S. Food and Drug Administration. (2015). Bridion (sugammadex injection) approval letter and prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Washington, DC: U.S. Department of Health and Human Services.